Publications by authors named "Michael Birrer"

Claim this Profile
A
An alternative perspective on the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 item Scale (FACIT-Sp-12) in people newly diagnosed with advanced cancer.
Mei Bai, David Cella, Sangchoon Jeon, Rang Govindarajan, Michael J Birrer

J Psychosoc Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
Ursula A Matulonis, Ignace Vergote, Kathleen N Moore, Lainie P Martin, Cesar M Castro, Michael J Birrer

Gynecol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell analysis of ovarian myeloid cells identifies age-associated changes in macrophages and signaling dynamics†.
Zijing Zhang, Lu Huang, Lynae Brayboy, Michael Birrer

Biol Reprod· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Q and a on PARP inhibitor use in somatic BRCA-mutated breast cancers.
Nadine Tung, Robert L Hollis, Giuseppe Viale, Carol Tweed, Natalia Lukashchuk, Michael Birrer

J Natl Cancer Inst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-affirmation intervention for patients newly diagnosed with advanced cancer: a preliminary efficacy trial.
Mei Bai, David Cella, Sangchoon Jeon, Rang Govindarajan, Michael J Birrer

J Psychosoc Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Kathleen N Moore, Domenica Lorusso, Ana Oaknin, Amit Oza, Nicoletta Colombo, Michael Birrer

Gynecol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.
Maj K Kjeldsen, Morten Jørgensen, Dina Sofie B Grønseth, Martin Schønemann-Lund, Gitte-Bettina Nyvang, Michael J Birrer

Cancer Res Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolically active neutrophils represent a permissive niche for Mycobacterium tuberculosis.
J Tucker Andrews, Zijing Zhang, G V R Krishna Prasad, Fischer Huey, Evgeniya V Nazarova, Michael J Birrer

Mucosal Immunol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.
Michael Birrer, Guiling Li, Mayu Yunokawa, Jung-Yun Lee, Byoung Gie Kim

JAMA Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Carly B Scalise, Kaitlyn Kincaid, Haley Thigpen, Jennah Moore, Bailee Dover, Michael Birrer

Gynecol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell analysis of ovarian myeloid cells identifies aging associated changes in macrophages and signaling dynamics.
Zijing Zhang, Lu Huang, Lynae Brayboy, Michael Birrer

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Shrabanti Chowdhury, Jacob J Kennedy, Richard G Ivey, Oscar D Murillo, Noshad Hosseini, Michael J Birrer

Cell· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses.
Sammy Ferri-Borgogno, Jared K Burks, Erin H Seeley, Trevor D McKee, Danielle L Stolley, Michael J Birrer

Cancers (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, Alla S Lisyanskaya, Sandro Pignata, Michael Birrer

Gynecol Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Shrabanti Chowdhury, Jacob J Kennedy, Richard G Ivey, Oscar D Murillo, Noshad Hosseini, Michael J Birrer

Cell· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Rebecca Arend, Jhalak Dholakia, Cesar Castro, Ursula Matulonis, Erika Hamilton, Michael Birrer

Gynecol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Krishnansu S Tewari, Michael W Sill, Michael J Birrer, Richard T Penson, Helen Huang

Gynecol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Kathryn Osann, Lari Wenzel, Chelsea McKinney, Lynne Wagner, David Cella, Michael Birrer

Gynecol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.
Christopher J LaFargue, Paola Amero, Kyunghee Noh, Lingegowda S Mangala, Yunfei Wen, Michael J Birrer

Nat Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Richard T Penson, Allison J Ambrosio, Christin A Whalen, Carolyn N Krasner, Panagiotis A Konstantinopoulos, Michael J Birrer

Oncologist· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting NaPi2b in ovarian cancer.
Susana Banerjee, Ronny Drapkin, Debra L Richardson, Michael Birrer

Cancer Treat Rev· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.
Sho Sato, Michael Gillette, Pamela R de Santiago, Eric Kuhn, Michael Burgess, Michael J Birrer

Sci Rep· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
John H Farley, William E Brady, David O'Malley, Keiichi Fujiwara, Kan Yonemori, Michael J Birrer

Gynecol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Susana Campos, Ursula Matulonis, Suzanne Berlin, Neil Horowitz, Joyce Liu, Michael J Birrer

Int J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study.
Yovanni Casablanca, Guisong Wang, Heather A Lankes, Chunqiao Tian, Nicholas W Bateman, Michael J Birrer

Cancers (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis